Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 [Yahoo! Finance]
Elicio Therapeutics, Inc. (ELTX)
Company Research
Source: Yahoo! Finance
Strong correlation observed between mRFS and strength of T cell response Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025 BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, presented updated results from the Phase 1 AMPLIFY-201 clinical trial ( NCT04853017 ) of ELI-002, an Amphiphile (“AMP”) cancer vaccine that targets KRAS-mutant tumors, at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland. ELI-002 was evaluated in individuals with mutant KRAS (“mKRAS”)-driven colorectal or pancreatic cancer with residual circulating tumor DNA and/or serum tumor biomarkers, who remain at high risk of disease recurrence following standard locoregional treatment. The updated clinical results, featured in an oral presentation by Shubham Pant, M.D., MBBS, of the University of T
Show less
Read more
Impact Snapshot
Event Time:
ELTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELTX alerts
High impacting Elicio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ELTX
News
- Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024GlobeNewswire
- Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentGlobeNewswire
- Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingGlobeNewswire
ELTX
Sec Filings
- 12/18/24 - Form 4
- 12/12/24 - Form 8-K
- 12/3/24 - Form 8-K
- ELTX's page on the SEC website